Prolonged response to trabectedin in a heavily pretreated patient with metastatic endometrial carcinoma: A case report and literature review

Giulia Meoni; Fabiana Letizia Cecere; Imane Chaib; Elisa Giommoni; Francesco Di Costanzo

doi:10.1016/j.gynor.2011.11.008

Prolonged response to trabectedin in a heavily pretreated patient with metastatic endometrial carcinoma: A case report and literature review

Gynecol Oncol Case Rep. 2011 Dec 3;2(1):23-5. doi: 10.1016/j.gynor.2011.11.008. eCollection 2011.

Authors

Giulia Meoni¹, Fabiana Letizia Cecere¹, Imane Chaib², Elisa Giommoni¹, Francesco Di Costanzo¹

Affiliations

¹ Medical Oncology 1, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
² Laboratory of Molecular Biology, Universitary Hospital Germans Trial I Pujol, Badalona, Spain.

Abstract

► We report the case of a heavily pretreated woman affected by metastatic endometrial carcinoma. ► Patient received Trabectedin as 10th line of treatment with an impressive clinical response. ► We evaluated BRCA1 and ERCC1 gene status which could be involved in Trabectedin sensitivity.

Keywords: BRCA1; Chemotherapy; ERCC1; Endometrial carcinoma; Trabectedin.